Bora Pharmaceuticals Capabilities Update August 2026: CPHI Special Edition

This session provides an inside look at how a global CDMO is expanding capacity, capabilities, and geographic reach to meet growing demand across the pharmaceutical development and manufacturing landscape. John Lowry, Vice President of Operations at Bora Pharmaceuticals, shares the company's approach to reliability, flexibility, and customer partnership, highlighting a network that supports everything from early development through commercial-scale manufacturing for both small- and large-molecule products.

Key insights include Bora's global manufacturing footprint across North America and Asia, recent investments in fill-finish, packaging, biologics, and solid-dose capabilities, and the strategic partnerships helping accelerate development and leverage AI-driven innovation. The discussion also addresses practical considerations for drug developers, including current manufacturing capacity, tech transfer timelines, quality system integration, and strategies for ensuring seamless project onboarding.

For companies evaluating outsourcing partners, the conversation offers valuable perspective on what to look for in a modern CDMO relationship and how operational experience, regulatory expertise, and network flexibility can help support successful product commercialization.